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Abstract
Background: Surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in Europe is performed through the
European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), which additionally provides data to inform the
European gonorrhoea treatment guideline; currently recommending ceftriaxone 500 mg plus azithromycin 2 g as first-line
therapy. We present antimicrobial susceptibility data from 24 European countries in 2015, linked to epidemiological data
of patients, and compare the results to Euro-GASP data from previous years.
Methods: Antimicrobial susceptibility testing by MIC gradient strips or agar dilution methodology was performed on
2134 N. gonorrhoeae isolates and interpreted using EUCAST breakpoints. Patient variables associated with resistance were
established using logistic regression to estimate odds ratios (ORs).
Results: In 2015, 1.7% of isolates were cefixime resistant compared to 2.0% in 2014. Ceftriaxone resistance was detected
in only one (0.05%) isolate in 2015, compared with five (0.2%) in 2014. Azithromycin resistance was detected in 7.1% of
isolates in 2015 (7.9% in 2014), and five (0.2%) isolates displayed high-level azithromycin resistance (MIC ≥ 256 mg/L)
compared with one (0.05%) in 2014. Ciprofloxacin resistance remained high (49.4%, vs. 50.7% in 2014). Cefixime resistance
significantly increased among heterosexual males (4.1% vs. 1.7% in 2014), which was mainly attributable to data from two
countries with high cefixime resistance (~11%), however rates among men-who-have-sex-with-men (MSM) and females
continued to decline to 0.5% and 1%, respectively. Azithromycin resistance in MSM and heterosexual males was higher
(both 8.1%) than in females (4.9% vs. 2.2% in 2014). The association between azithromycin resistance and previous
gonorrhoea infection, observed in 2014, continued in 2015 (OR 2.1, CI 1.2–3.5, p < 0.01).
Conclusions: The 2015 Euro-GASP sentinel system revealed high, but stable azithromycin resistance and low overall
resistance to ceftriaxone and cefixime. The low cephalosporin resistance may be attributable to the effectiveness of the
currently recommended first-line dual antimicrobial therapy; however the high azithromycin resistance threatens the
effectiveness of this therapeutic regimen. Whether the global use of azithromycin in mono- or dual antimicrobial therapy
of gonorrhoea is contributing to the global increases in azithromycin resistance remains to be elucidated. The increasing
cefixime resistance in heterosexual males also needs close monitoring.
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Background
Since the introduction of antimicrobial therapy of gonor-
rhoea, the rapid emergence and dissemination of anti-
microbial resistance (AMR) in the causative agent,
Neisseria gonorrhoeae, has been well-documented [1].
Due to the extraordinary ability of N. gonorrhoeae to
rapidly and effectively develop AMR, combined multi-
disciplinary efforts are required to retain gonorrhoea as
a treatable infection. These include: antimicrobial
susceptibility surveillance of N. gonorrhoeae, including
appropriate analysis of patient risk-group, the early iden-
tification of treatment failures, monitoring of antimicro-
bial usage, appropriate diagnostic testing strategies and
evidence-based patient management [2, 3].
Surveillance of N. gonorrhoeae AMR in the European
Union/European Economic Area (EU/EEA) is performed
through the European Gonococcal Antimicrobial
Surveillance Programme (Euro-GASP) and co-ordinated
by the European Centre for Disease Prevention and
Control (ECDC). Euro-GASP provides quality-assured
antimicrobial susceptibility data, linked to patient
clinical and epidemiological data. The programme aims
to identify emergence of new AMR, monitor antimicro-
bial susceptibility and resistance over time in Europe,
and to inform European [4] as well as national and other
international gonorrhoea management guidelines. The
European guidelines on the diagnosis and treatment of
gonorrhoea currently recommend a single intramuscular
dose of 500 mg of ceftriaxone plus a single oral dose of
2 g of azithromycin as empirical first-line dual
antimicrobial therapy for all cases of urogenital and
extra-genital gonorrhoea [4]. Euro-GASP documented a
statistically significant increase in azithromycin
resistance from 2013 (2.8%) to 2014 (7.9%) alongside a
significant decrease in cefixime resistance from 4.7% to
2.0% [5]. Dual therapy with ceftriaxone and azithromycin
has been recommended in Europe since 2012 as a strat-
egy to delay the emergence and/or spread of ceftriaxone
resistance [4]. However, the increasing azithromycin
resistance documented in 2014 in Europe threatens this
strategy, and in essence could leave ceftriaxone being
used as monotherapy. Furthermore, the first failure
(globally) to treat gonorrhoea with empirical dual anti-
microbial therapy (250 mg ceftriaxone by single intra-
muscular dose plus 1 g of azithromycin by single oral
dose) was recently reported in a male in the United
Kingdom (UK) with pharyngeal gonorrhoea caused by a
ceftriaxone- and azithromycin-resistant strain [6].
The present study describes the Euro-GASP anti-
microbial susceptibility and resistance data from 24
European countries in 2015, linked to clinical and
epidemiological data of the patients, and compares these
results to Euro-GASP data from previous years, with
particular focus on 2014.
Methods
European Gonococcal Antimicrobial Surveillance
Programme (Euro-GASP)
N. gonorrhoeae isolates from 24 participating countries
were included in the Euro-GASP in 2015 (Table 1).
Isolates from consecutive patients were collected from
September to November 2015 and antimicrobial suscep-
tibility testing was performed using Etests (or other MIC
gradient strips in some countries) or an agar dilution
method (determination of minimum inhibitory
concentration (MIC) or breakpoint technique) for ceftri-
axone, cefixime, azithromycin, and ciprofloxacin as pre-
viously described [5]. Isolates from seven (29%)
countries (Table 1) were tested centrally at Public Health
England or Örebro University Hospital, Sweden. The
remaining 17 (71%) countries followed a decentralised
testing model, after fulfilling established quality criteria,
where antimicrobial susceptibility testing was performed
in their own laboratory (Table 1). All Euro-GASP
laboratories participated in an annual external quality
assessment (EQA) programme [7] to ensure comparabil-
ity of antimicrobial susceptibility data. The antimicrobial
susceptibility testing results were interpreted using
EUCAST resistance breakpoints; cefixime/ceftriaxone
MIC >0.12 mg/L, azithromycin MIC >0.5 mg/L, and cip-
rofloxacin MIC >0.06 mg/L [8]. The following clinical
and/or epidemiological variables of the patients were
collected and categorised: age (<25 years or ≥25 years),
sexual orientation and gender (men who have sex with
men (MSM), male heterosexuals and all women), previ-
ous gonorrhoea (yes or no), and concurrent chlamydial
infection or no chlamydial infection.
Statistical analysis
Statistical analysis was performed in STATA v13.1
(StataCorp LP, TX, USA) and included the Z-test to
establish significance of changes in the proportion of
isolates with AMR between 2014 and 2015. Patient
variables associated with AMR were established using
univariate and multivariable logistic regression
analyses and associations were expressed as odds
ratios (OR) with 95% confidence intervals (CI). A
Pearson χ2-test was used to test whether these odds
ratios were significantly different from one. For small
cell numbers, Fisher’s exact test was used. A P-value
of <0.05 was considered to indicate significance for
all tests.
Results
A total of 2134 N. gonorrhoeae isolates were examined in
2015. Most (81.8%) isolates were collected from male
patients. The age of the patients ranged from less than
one year to 79 years, with a median age of 29 years.
Overall, 29.5% of patients were under 25 years of age and
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males (median age 30 years) were significantly older than
women (median age 24.5 years) (p < 0.001). The anatom-
ical site of specimen collection was mainly urogenital
(72.9%), followed by rectal (13.5%) and pharyngeal (8.7%).
Among cases with information on previous diagnosis of
gonorrhoea (42.0%) and concurrent STI (37.8%), 17.5%
had previously been diagnosed with gonococcal infection
and 19.0% had a concurrent Chlamydia trachomatis infec-
tion. Among cases with known sexual orientation and
gender (68.5%), 55% were heterosexual men (29%) or
women (26%), and 45% were MSM.
The antimicrobial susceptibility testing results are
summarised in Table 1. Cefixime resistance was detected
in 1.7% (36 out of 2132) of isolates (Table 1, Fig. 1)
representing a stable overall resistance level compared
with 2014 (2.0%, 42/2101) (p = 0.45). Cefixime resistance
was detected in nine (37.5%) countries (10 (43%)
countries in 2014 and 13 (62%) in 2013), and in these
countries the cefixime resistance levels ranged from 0.4%
in the UK to ≥11.0% in Belgium and Greece (Table 1).
There were seven isolates (0.3%; from Greece (n = 5),
Slovakia (n = 1) and Spain (n = 1)) with cefixime MICs of
Table 1 Resistance to cefixime, azithromycin and ciprofloxacin in N. gonorrhoeae isolates from 24 EU/EEA countries, 2015
Country No. of
isolates
tested
Resistance Method of testing
Cefixime Azithromycin Ciprofloxacin
No. % No. % No. %
Austria 61 0 0.0% 2 3.3% 40 65.6% Decentralised – Etest
Belgium 99 11 11.1% 3 3.0% 49 49.5% Decentralised – AD
Croatia 8 0 0.0% 0 0.0% 3 37.5% Centralised – Etest
Cyprus 3 0 0.0% 0 0.0% 2 66.7% Decentralised – Etest
Denmark 110 0 0.0% 3 2.7% 34 30.9% Decentralised – Etest
Estonia 18 0 0.0% 0 0.0% 5 27.8% Centralised – Etest
France 105 0 0.0% 6 5.7% 44 41.9% Decentralised – Etest
Germany 109 2 1.8% 2 1.8% 67 61.5% Centralised – BKP/Etest
Greecea 100 11 11.0% 22 22.0% 77 77.0% Decentralised – Etest
Hungary 64 1 1.6% 3 4.7% 34 53.1% Centralised - BKP/Etest
Iceland 14 0 0.0% 0 0.0% 4 28.6% Decentralised – Etest
Ireland 110 1 0.9% 20 18.2% 50 45.5% Decentralised – Etest
Italy 100 0 0.0% 2 2.0% 71 71.0% Decentralised – Etest
Latvia 9 0 0.0% 0 0.0% 1 11.1% Centralised – Etest
Malta 29 0 0.0% 4 13.8% 19 65.5% Decentralised – Etest
Netherlands 200 0 0.0% 8 4.0% 74 37.0% Decentralised – Etest
Norway 110 1 0.9% 4 3.6% 64 58.7%b Decentralised – AD
Poland 56 0 0.0% 3 5.4% 32 57.1% Centralised – Etest
Portugal 110 0 0.0% 19 17.3% 41 37.3% Decentralised – Etest
Slovakia 104 4 3.8% 2 1.9% 56 53.8% Centralised – Etest
Slovenia 109 0 0.0% 0 0.0% 38 34.9% Decentralised – Etest
Spain 167 4 2.4% 5 3.0% 109 65.3% Decentralised – Etest
Sweden 100 0 0.0% 14 14.0% 45 45.0% Decentralised – Etest
UK 239 1 0.4% 30 12.6% 95 39.7% Decentralised – AD/Etest
Total:
Cefixime 2132 36 1.7%
Ciprofloxacin 2133 1054 49.4%
Azithromycin 2134 152 7.1%
95% CI 1.2–2.3 6.1–8.3 47.3–51.5
EU/EEA European Union/European Economic Area, No. Number, Etest minimum inhibitory concentration (MIC) gradient strips to determine the MIC of an
antimicrobial (mostly Etests, but also some other MIC gradient strips were used in some countries), AD agar dilution method to determine the MIC of an
antimicrobial, BKP Breakpoint agar dilution method, CI confidence interval of the mean %
aOnly one (0.05%) ceftriaxone resistant isolate was identified in Euro-GASP in 2015 (in Greece; MIC = 0.25 mg/L)
bCalculated from 109 isolates with ciprofloxacin results
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0.5 mg/L compared with three (0.1%) isolates in 2014; the
proportion of highly susceptible isolates (cefixime MIC
≤0.016 mg/L) continued to increase (from 61% in 2013 to
71% in 2014 and 75% in 2015). Only one (0.05%)
isolate displayed ceftriaxone resistance compared
with five (0.2%) isolates in 2014 and seven (0.4%) in
2013. This single ceftriaxone-resistant isolate
(MIC = 0.25 mg/L) in 2015 was from Greece and
additionally had intermediate susceptibility to azi-
thromycin (MIC = 0.5 mg/L). There were an add-
itional 16 (0.7%) isolates with ceftriaxone MICs of
0.125 mg/L (i.e. on the breakpoint for resistance)
and nine (0.4%) of these isolates were also resistant
to azithromycin. The MIC distribution for ceftriax-
one in 2015, compared with 2009–2014, showed a
higher proportion of more susceptible gonococcal
isolates (MIC ≤ 0.016 mg/L) and a decreased pro-
portion of isolates with higher MICs (0.032 mg/L to
0.125 mg/L) (Fig. 2).
The overall resistance to azithromycin was 7.1% (152/
2134 isolates), which represented the first break from
the increasing trend in azithromycin resistance that has
been observed in Euro-GASP data since 2012, although
the decrease when compared with 2014 (7.9%) was not
significant (p = 0.35). Azithromycin resistance ranged
from 0% (Croatia, Cyprus, Estonia, Iceland, Latvia and
Slovenia; of which all except Slovenia examined ≤18
isolates) to 22% in Greece (Table 1). Five (0.2%) isolates
displayed high-level resistance to azithromycin (HLAziR
(MIC ≥ 256 mg/L); Ireland (n = 3), Norway (n = 1) and
UK (n = 1)) compared with one (0.05%) in 2014. The
MIC distribution for azithromycin in 2015, compared
with 2011 (when MIC determination was introduced) to
2014, showed an increasing proportion of resistant
isolates (MICs >0.5 mg/L). However, most (87%) of the
resistant isolates in 2015 had a low-level resistance
(MICs ≤2 mg/L), which was similar to previous years
(Fig. 3). Five isolates (Greece (n = 2), Hungary (n = 1),
Slovakia (n = 1) and UK (n = 1)) were resistant to both
azithromycin and cefixime. Ciprofloxacin resistance was
detected in 49.4% (1054/2133) of isolates in 2015, which
was similar to resistance levels observed in 2014 (50.7%)
and 2013 (53%) (Fig. 1).
In 2015, cefixime resistance significantly increased
among heterosexual males (4.1% vs. 1.7% in 2014,
p = 0.045) whereas it decreased among females (1%;
2.5% in 2014, p = 0.16, Fisher’s Exact test) and MSM
(0.5%; 1.2% in 2014, p = 0.21, Fisher’s Exact test).
Cefixime resistance was significantly associated
(p < 0.01) with heterosexual males in 2015 compared
with females (OR = 0.3, CI = 0.08–0.8) and MSM
(OR = 0.1, CI = 0.03–0.4), whereas no patient character-
istics were significantly associated with cefixime resist-
ance in 2014. Higher levels of azithromycin resistance
were also detected in 2015 in male heterosexuals (8.1%;
8.9% in 2014) and MSM (8.1%; 9.9% in 2014) compared
to in females (4.9%; 2.2% in 2014), but this difference
was not significant (male heterosexuals p = 0.07 and
MSM p = 0.06). The association between azithromycin
resistance and previous gonorrhoea infection first ob-
served in 2014 continued in 2015 (OR 2.1, CI 1.2–3.5,
p < 0.01). The only patient association with ciprofloxacin
resistance in 2015 was being a heterosexual male
compared with MSM (OR 1.9, CI 1.5–2.4, p < 0.01), in
Fig. 1 Trends in cefixime, azithromycin, and ciprofloxacin gonococcal resistance in the EU/EEA, 2009–2015. Note: logarithmic scale on y-axis.
Number of ceftriaxone resistant isolates (MIC > 0.125 mg/L); 2009 and 2010 (n = 0), 2011 (n = 10), 2012 (n = 3), 2013 (n = 7), 2014 (n = 5), and
2015 (n = 1)
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contrast to 2014 when higher age (≥25 years) and the
absence of a concurrent chlamydial infection were also
associated with ciprofloxacin resistance.
Discussion
The 2015 Euro-GASP surveillance data, examining
AMR gonococci in 24 (77%) EU/EEA countries,
showed that the growing increase in azithromycin
resistance documented since 2012 appears to have
stalled, and the resistance levels to ceftriaxone and
cefixime remain stable and low. This low level of
resistance to third-generation extended-spectrum
cephalosporins appears to reflect the situation
documented from well-established national surveil-
lance programmes in many geographic settings and is
likely a consequence of the effectiveness of the
current first-line dual antimicrobial therapy in com-
bination with appropriate diagnostics and patient
management. For example, in the USA resistance to
cefixime (MIC >0.125 mg/L) and decreased suscepti-
bility to ceftriaxone (MIC ≥0.125 mg/L, as described
by the Centers for Disease Control and Prevention
(CDC), Atlanta, USA) was documented in 0.8% and
0.1% of isolates, respectively, in 2014 [9]. Low levels
of resistance to cefixime and decreased susceptibility
to ceftriaxone (1.1% and 2.7%, respectively) was also
documented in Canada in 2014 [10] using the
identical breakpoints as CDC [9], and no ceftriaxone
resistance (MIC >0.12 mg/L) was reported from
Australia in 2014 [11]. No ceftriaxone resistance
Fig. 2 Ceftriaxone MIC distribution for N. gonorrhoeae isolates in the EU/EEA, 2009–2015
Fig. 3 Azithromycin MIC distribution for N. gonorrhoeae isolates in the EU/EEA, 2011–2015
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(MIC >0.12 mg/L) was recently documented in Fuku-
oka, Japan [12], although the high, but decreasing,
proportion of cefixime resistance (26% in 2013) is still
of concern. Unfortunately, a higher level of ceftriax-
one resistance was documented in China; 4.4% in
2012 to 2013 [13].
Despite positive results for the extended-spectrum
cephalosporins, the high rates of azithromycin resist-
ance documented by Euro-GASP threaten the effect-
iveness of the recommended dual antimicrobial
therapy, and increasing azithromycin resistance is also
reported globally. An analysis of azithromycin suscep-
tibility in N. gonorrhoeae from 2005 to 2013 in the
USA [14] revealed no temporal trend in azithromycin
reduced susceptibility/resistance (MIC > 2 mg/L),
which ranged from 0.3% to 0.6% during the examined
years. This suggested that there was no impact on the
level of azithromycin resistance by the use of dual
antimicrobial therapy in the USA (initiated in 2010)
and prompting the authors to state “it is possible that
we overestimated the capacity of N. gonorrhoeae to
acquire azithromycin resistance”; a reasonable state-
ment especially as azithromycin is the most
commonly prescribed antimicrobial agent in the USA
[15]. However, the 2014 data for the USA [9] revealed
a substantial increase in azithromycin resistance to
2.5%, which is the highest level since 1992 when
testing for azithromycin resistance started. The
authors also noted that azithromycin resistance was
most prevalent in the mid-west of the USA, suggest-
ing ‘home-grown’ resistance within the USA, as
opposed to the traditional importation of resistant
gonococcal strains in the western part of the USA
from South East Asia and subsequent clonal national
spread as seen with ciprofloxacin resistance and
penicillinase-producing N. gonorrhoeae (PPNG) [9].
Again, a similar picture was observed in Canada
during the same time period; an increase in azithro-
mycin resistance from 0.4% in 2011 to 3.3% in 2014
[10]. In Fukuoka, Japan, azithromycin resistance (MIC
>0.5 mg/L) increased from 1.8% in 2010 to 22.6% in
2013 [12], which in part was attributed to the use of
2 g of azithromycin (extended-release formulation) as
monotherapy for gonorrhoea. The level of azithromy-
cin resistance has also been increasing in Australia;
from 1.1%–1.3% in 2011–2012 to 2.4% in 2014 [11].
National studies in European countries have also ob-
served increases in azithromycin resistance, e.g. from
1% in 2014 to 9.8% in the UK in 2015, although this
increase was partly due to a change in the agar
medium used for antimicrobial susceptibility testing
[16]. The five HLAziR isolates documented in Euro-
GASP in 2015 represent the highest number since the
beginning of the Euro-GASP surveillance and reports
of outbreaks or sporadic detection of HLAziR globally
[10, 11, 16–20] are of obvious concern. The mecha-
nisms of the azithromycin resistance in the 2015
Euro-GASP isolates have not been investigated. How-
ever, as in previous studies the high-level azithromycin
resistant isolates likely contain an A2059G (Escherichia
coli numbering) mutation in three or four of the 23S
rRNA gene alleles, whereas the isolates with lower level of
azithromycin resistance comprise the C2611T mutation in
23S rRNA and/or mutations in the promoter or coding
sequence of mtrR [1, 20].
A recent study from Guangzhou, China reported that
32.5% of isolates with azithromycin resistance (MIC
≥1.0 mg/L) also had decreased susceptibility to ceftriaxone
(MIC ≥0.125 mg/L) [21]. In addition, reports from On-
tario, Canada [22] and Hawaii [19] have described clonal
spread of isolates with both azithromycin resistance and
reduced susceptibility to cephalosporin. Clonal spread of
isolates with azithromycin and ceftriaxone resistance has
been previously documented in some N. gonorrhoeae
multi-antigen sequence typing (NG-MAST) ST1407 iso-
lates [19, 23, 24], and spread of these types of clones is of
most concern to the global gonococcal surveillance
community and healthcare clinicians.
Whether the global use of azithromycin in mono-
or dual antimicrobial therapy for gonorrhoea is con-
tributing to the increasing azithromycin resistance is
difficult to establish in the absence of data compar-
ing the impact of the different regimens on the sus-
ceptibility profile of the circulating gonococcal
population. The widespread use of ceftriaxone in
combination with azithromycin for empirical first-
line treatment of all cases of uncomplicated gonor-
rhoea, as currently recommended in the European
gonorrhoea management guideline [4] and similar
therapeutic regimens [25, 26], has likely maintained
gonorrhoea a treatable infection for the present.
Nevertheless, it remains to be seen if the combin-
ation with azithromycin or the increased dosage of
ceftriaxone that accompanied the dual antimicrobial
therapy implementation in many regimens, has con-
tributed most to the currently low level of resistance
to extended-spectrum cephalosporins. Even though
ceftriaxone and cefixime have been shown to have
comparable efficacies for fully susceptible gonococcal
isolates [27–29] and free-drug concentration time
periods that exceed MIC (fT > MIC) in most gono-
coccal strains [30], cefixime may be more prone to
promote resistance development than ceftriaxone.
This is supported by the globally documented
decreasing cefixime resistance which followed the
removal of cefixime from recommended first-line
empirical therapy, and the higher number of treat-
ment failures with cefixime versus ceftriaxone [1].
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The increasing cefixime resistance observed in hetero-
sexual males (4.1%) was mainly a result of overall high
resistance rates in the isolates from two countries;
Belgium (11.1%, all isolates MIC = 0.25 mg/L) and
Greece (11%; 6 isolates MIC = 0.25 mg/L and 5 isolates
MIC = 0.5 mg/L). Greece did not submit any isolates
from women and therefore any high cefixime resistance
among women from Greece would not have contributed
to the overall European rate. However the lower propor-
tion of isolates from women (18.2%) compared with
men (81.8%) may contribute overall to an underestima-
tion of resistance in women and in general in heterosex-
ual networks, as is the case in all GASPs, particularly in
the USA where isolates from females are not included
[14]. The Euro-GASP collaborators in Greece and
Belgium have stated that cefixime, which could more ef-
fectively select for resistance, is not frequently used as
first-line treatment for gonorrhoea in their countries.
Furthermore, the overall level of cefixime resistance in
MSM was low (0.5%), which might be because cefixime
resistance was previously frequent in this group and,
consequently, dual antimicrobial therapy (ceftriaxone
plus azithromycin) or at a minimum ceftriaxone has
been used to treat gonorrhoea more frequently in this
group. Unfortunately, data on prescribed treatment in
Euro-GASP are not available pre-2013, and the level of
reporting for this variable was low in 2014 (18.6%) and
2015 (36.5%) [5].
The frequent use of azithromycin for empirical
treatment of non-gonococcal urethritis may be driving
the higher azithromycin resistance in men. However,
the use of azithromycin to treat C. trachomatis and
Mycoplasma genitalium infections in both genders
should also be considered. It should be noted that
the two countries with the highest azithromycin
resistance, Greece (22%) and Ireland (18%), both
submitted isolates predominantly from men and that
MICs for the majority of azithromycin-resistant
isolates were just above the resistance breakpoint.
Results of azithromycin susceptibility tests vary with
changes in agar medium composition, pH and incuba-
tional parameters such as CO2 levels [31] so even
though MICs in the laboratories are comparable,
slight technical differences may increase or decrease
MICs by one or more two-fold dilution steps and
affect the clinical interpretation.
Improving the representativeness of Euro-GASP by,
for example, including more isolates from females,
increasing its geographic representativeness and
increasing the completeness of reporting of patient
variables are part of the ongoing Euro-GASP work
programme in order to reduce country biases as far
as possible. However, due to the heterogeneity of
healthcare systems across Europe, a ‘one-size-fits-all
approach’ may never be possible and differences in
isolate collection, selection and geographical represen-
tativeness may be an inherent limitation of any large
multi-country sentinel surveillance programme such
as Euro-GASP.
Conclusions
Even though ceftriaxone resistance is still low and the
MIC distribution is currently showing little signs of
concern, the 2015 azithromycin data emphasize the
need to continue expanding and improving Euro--
GASP and other GASPs as emphasised in the Euro-
pean and WHO action plans to detect and prevent
the emergence and spread of AMR in N. gonorrhoeae
[2, 3]. The increasing global resistance to azithromy-
cin is of major concern and threatens the future ef-
fectiveness of the recommended dual antimicrobial
therapies introduced in many well-resourced settings
[4, 25, 26, 32–34]. We should be particularly alert to
the spread of ceftriaxone and azithromycin co-
resistance and continue to monitor closely for treat-
ment failures, such as the recently reported first treat-
ment failure globally to the recommended dual
antimicrobial therapy regimen [6].
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